血管性血友病因子在缺血性脑卒中防治中的研究进展  

Research progress of von Willebrand factor for prevention and treatment of ischemic stroke

作　　者：闫彬 陆士奇[2] 赵益明[3] Yan Bin;Lu Shiqi;Zhao Yiming(Department of Clinical Laboratory Medicine, the Affiliated Nanyang Central Hospital of Zhengzhou University, Nanyang, Henan 473000, China;Department of Emergency Medicine, the First Affiliated Hospital of Soochow University, Suzhou 215006, China;The First Affiliated Hospital of Soochow University, Jiangsu Provincial Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis, Ministry of Health, Suzhou 215006, China)

机构地区：[1]郑州大学附属南阳市中心医院检验科,473000 [2]苏州大学附属第一医院急诊科,215006 [3]苏州大学附属第一医院,江苏省血液研究所,卫生部血栓与止血重点实验室,215006

出　　处：《中华神经科杂志》2019年第9期780-786,共7页Chinese Journal of Neurology

基　　金：国家自然科学基金面上项目(81270593,81873431);江苏省自然科学基金面上项目(BK20181164).

摘　　要：血管性血友病因子(von Willebrand factor,VWF)主要是由内皮细胞产生的多聚体糖蛋白,能够调节高剪切力下的血栓形成,被称为沟通血小板和内皮下胶原的桥梁.研究发现,缺血性脑卒中患者体内存在VWF的异常,并且VWF在评估脑卒中的预测、治疗和预后中显示出独特意义.众多基础和临床证据表明VWF是缺血性脑卒中防治的潜在靶点.近年来,VWF在缺血性脑卒中防治中的研究获得了快速发展,文中就这一领域的发现做一综述.Von Willebrand Factor (VWF) is a multimeric glycoprotein produced by endothelial cells, which increases in thrombogenicity especially under high shear rates. It bridges between vascular platelets and sub-endothelial collagen. There is abnormal VWF level in ischemic stroke patients, and VWF shows unique significance in valuing the prediction, treatment and prognosis of ischemic stroke. Numerous basic and clinical evidences suggest that VWF is a potential target for ischemic stroke treatment. In recent years, researches on VWF for prevention and treatment of ischemic stroke have been rapidly developed. The findings in this field are reviewed in this paper.

关 键 词：血管性血友病因子 卒中 靶点 

分 类 号：R743.3[医药卫生—神经病学与精神病学]